Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.
Frequently asked questions
What sector does Tellgen Corp (300642) operate in?
Tellgen Corp belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Tellgen Corp (300642) current stock price?
As of the latest data, Tellgen Corp stock price is CN¥13.73, with a previous close of CN¥13.64. Tellgen Corp gained CN¥0.09 in the last trading session, representing a 0.66% increase.
What is Tellgen Corp (300642) current market capitalization?
Tellgen Corp market cap is approximately 2.23 billion.
What is Tellgen Corp (300642) Earnings Per Share (EPS)?
The trailing EPS is -CN¥0.02.
Does Tellgen Corp (300642) pay dividends?
Yes. Tellgen Corp pays annual dividends with an annualized yield of 0.73% and an estimated annual payout of CN¥0.10 per share.
When is the next ex-dividend date for Tellgen Corp (300642)?
The next ex-dividend date is scheduled for May 26, 2027.
What is Tellgen Corp (300642) beta (volatility) score?
Tellgen Corp has a beta of 0.224, indicating lower volatility than the overall market.